Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Mar 23;5(3):e002995.
doi: 10.1161/JAHA.115.002995.

Does Antihypertensive Drug Class Affect Day-to-Day Variability of Self-Measured Home Blood Pressure? The HOMED-BP Study

Affiliations
Randomized Controlled Trial

Does Antihypertensive Drug Class Affect Day-to-Day Variability of Self-Measured Home Blood Pressure? The HOMED-BP Study

Kei Asayama et al. J Am Heart Assoc. .

Abstract

Background: Recent literature suggests that blood pressure variability (BPV) predicts outcome beyond blood pressure level (BPL) and that antihypertensive drug classes differentially influence BPV. We compared calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockade for effects on changes in self-measured home BPL and BPV and for their prognostic significance in newly treated hypertensive patients.

Methods and results: We enrolled 2484 patients randomly allocated to first-line treatment with a calcium channel blocker (n=833), an angiotensin-converting enzyme inhibitor (n=821), or angiotensin receptor blockade (n=830). Home blood pressures in the morning and evening were measured for 5 days off treatment before randomization and for 5 days after 2 to 4 weeks of randomized drug treatment. We assessed BPL and BPV changes as estimated by variability independent of the mean and compared cardiovascular outcomes. Home BPL response in each group was significant (P≤0.0001) but small in the angiotensin-converting enzyme inhibitor group (systolic/diastolic: 4.6/2.8 mm Hg) compared with the groups treated with a calcium channel blocker (systolic/diastolic: 8.3/3.9 mm Hg) and angiotensin receptor blockade (systolic/diastolic: 8.2/4.5 mm Hg). In multivariable adjusted analyses, changes in home variability independent of the mean did not differ among the 3 drug classes (P≥0.054). Evening variability independent of the mean before treatment significantly predicted hard cardiovascular events independent of the corresponding home BPL (P≤0.022), whereas BPV did not predict any cardiovascular outcome based on the morning measurement (P≥0.056). Home BPV captured after monotherapy had no predictive power for cardiovascular outcome (P≥0.22).

Conclusions: Self-measured home evening BPV estimated by variability independent of the mean had prognostic significance, whereas antihypertensive drug classes had no significant impact on BPV changes. Home BPL should remain the primary focus for risk stratification and treatment.

Clinical trial registration: URL: http://www.umin.ac.jp/ctr/index.htm. Unique identifier: C000000137.

Keywords: antihypertensive drugs; blood pressure variability; cardiovascular outcomes; home blood pressure; morning and evening self‐measurement.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time course of home blood pressure measurement before and after randomization. During the study period, morning blood pressure was measured in a sitting position once every morning after ≥2 minutes of rest and within 1 hour of awakening, before breakfast, and before taking antihypertensive medication, if patients were taking antihypertensive medication. Evening blood pressure was measured in a sitting position once every evening just before going to bed and after ≥2 minutes of rest. Data on home blood pressure values for, in principle, 5 days before randomization and for 5 days after 10 to 28 days of randomized drug treatment were used for the calculation; patients with 3 to 4 days of home blood pressure data in each interval were also included. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blockade; CCB, calcium channel blocker.
Figure 2
Figure 2
The 10‐year estimated absolute risk of hard cardiovascular events associated with the mean level of systolic home blood pressure and VIM in the morning (A) or the evening (B), measured at baseline. The risk functions were standardized to the distribution (mean or ratio) of sex, age, body mass index, corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of cardiovascular disease, and antihypertensive drug classes. Among 2484 patients, 43 hard cardiovascular events occurred. Mean systolic blood pressure along the horizontal axis covers 135 to 170 mm Hg. Four continuous lines represent the risk independently associated with VIM equal to 5, 8, 11, and 14 U. P values are for the independent effect of systolic blood pressure (PSBP) and VIM (PVIM). VIM indicates variability independent of the mean.
Figure 3
Figure 3
The 10‐year estimated absolute risk of hard cardiovascular events associated with the mean level of systolic home blood pressure and VIM in the morning (A) or the evening (B), measured after monotherapy. The risk functions were standardized to the distribution (mean or ratio) of sex, age, body mass index, corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of cardiovascular disease, and antihypertensive drug classes. Among 2484 patients, 43 hard cardiovascular events occurred. Mean systolic blood pressure along the horizontal axis covers 125 to 160 mm Hg. Four continuous lines represent the risk independently associated with VIM equal to 5, 8, 11, and 14 U. P values are for the independent effect of systolic blood pressure (PSBP) and VIM (PVIM). VIM indicates variability independent of the mean.
Figure 4
Figure 4
The 10‐year estimated absolute risk of hard cardiovascular events associated with the mean level of systolic home blood pressure and ARV in the morning (A) or the evening (B), measured at baseline. The risk functions were standardized to the distribution (mean or ratio) of sex, age, body mass index, corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of cardiovascular disease, and antihypertensive drug classes. Among 2484 patients, 43 hard cardiovascular events occurred. Mean systolic blood pressure along the horizontal axis covers 135 to 170 mm Hg. Four continuous lines represent the risk independently associated with ARV equal to 6, 9, 12, and 15 mm Hg. P values are for the independent effect of systolic blood pressure (PSBP) and ARV (PARV). ARV indicates average real variability.
Figure 5
Figure 5
The 10‐year estimated absolute risk of hard cardiovascular events associated with the mean level of systolic home blood pressure and ARV in the morning (A) or the evening (B), measured after monotherapy. The risk functions were standardized to the distribution (mean or ratio) of sex, age, body mass index, corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of cardiovascular disease, and antihypertensive drug classes. Among 2484 patients, 43 hard cardiovascular events occurred. Mean systolic blood pressure along the horizontal axis covers 125 to 160 mm Hg. Four continuous lines represent the risk independently associated with ARV equal to 6, 9, 12, and 15 mm Hg. P values are for the independent effect of systolic blood pressure (PSBP) and ARV (PARV). ARV indicates average real variability.

Similar articles

Cited by

References

    1. Staessen JA, Thijs L, Ohkubo T, Kikuya M, Richart T, Boggia J, Adiyaman A, Dechering DG, Kuznetsova T, Thien T, de Leeuw P, Imai Y, O'Brien E, Parati G. Thirty years of research on diagnostic and therapeutic thresholds for the self‐measured blood pressure at home. Blood Press Monit. 2008;13:352–365. - PubMed
    1. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:10–29. - PMC - PubMed
    1. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit‐to‐visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905. - PubMed
    1. Hara A, Thijs L, Asayama K, Jacobs L, Wang JG, Staessen JA. Randomised double‐blind comparison of placebo and active drugs for effects on risks associated with blood pressure variability in the Systolic Hypertension in Europe trial. PLoS One. 2014;9:e103169. - PMC - PubMed
    1. Asayama K, Kikuya M, Schutte R, Thijs L, Hosaka M, Satoh M, Hara A, Obara T, Inoue R, Metoki H, Hirose T, Ohkubo T, Staessen JA, Imai Y. Home blood pressure variability as cardiovascular risk factor in the population of Ohasama. Hypertension. 2013;61:61–69. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources